Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000851328 | SCV001712030 | likely pathogenic | Pitt-Hopkins syndrome | 2021-05-11 | reviewed by expert panel | curation | The p.Gly496Cys variant in TCF4 occurs in the confirmed de novo state in an individual with a neurodevelopmental disorder consistent with TCF4 abnormality (PS2). The p.Gly496Cys variant in TCF4 is absent from gnomAD (PM2_supporting). This variant occurs at the last amino acid residue in exon 16 and is predicted to affect the canonical splice donor site in intron 16 by several splice prediction programs. In summary, the p.Gly496Cys variant in TCF4 is classified as Likely Pathogenic based on the ACMG/AMP criteria (PS2, PM2_supporting, PP3). |
Hudson |
RCV000851328 | SCV000993624 | likely pathogenic | Pitt-Hopkins syndrome | 2019-02-04 | criteria provided, single submitter | research |